The TGA has approved a new Alzheimer’s drug, Lecanemab, which has been shown to slow cognitive decline in its early stages. With an annual cost of nearly $40,000, experts warn it cannot be accessed unless added to the Pharmaceutical Benefits Scheme.
Breakdown
- Susanna Sperber was diagnosed with early-onset Alzheimer's at age 55.
- She is participating in a clinical trial and focusing on new experiences. 18s
- Licanumab, a drug that clears amyloid plaques, offers hope for early-stage patients. 34s
- Studies show licanumab slows cognitive decline by 35%, but it is not a cure. 54s
- The drug is not yet subsidised in Australia, costing $40,000 per year. 1m 7s